Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co., Fed. Cir., No. 2008-1248, 3/22/2010.

From the American Intellectual Property Law Association’s website:

“Section 112, first paragraph of the Patent Act requires that a patent specification not only describe the manner of making and using a claimed invention, but also separately requires a written description of the claimed invention itself, the en banc Federal Circuit held March 22, 2010, in a 9-2 decision.”

“The Court rejected the argument that the required written description of the invention is only for purposes of identifying what is to be enabled, concluding that the statutory phrase “to enable” pertains only to the required description of making and using the invention. If Congress meant to require only a description of enablement, the statute would have been written differently, Judge Lourie pointed out. He added that the Patent Act has always required a description of the invention as a basic element of the quid pro quo bargain for exclusive rights.”

I’ve been writing patent applications to include a written description of the invention itself since I started writing patents. It’s just common sense: a patent, which is an exercise in disclosure, requires that the inventor disclose not only what the invention is but also the best mode of making and using the invention. How do you do that without providing a written description of the invention?

Read the slip opinion here.

USPTO Pilots Program to Accelerate the Patent Process for Small Entity Inventors, USPTO Press Release, 09-26

Backlog Reduction for Small Entity Inventors Pilot Will Allow Small Entities to Gain Advancement for a Pending Application In Exchange for Abandoning Another Application.

Now isn’t this interesting. If a small inventor (presumably this means someone who can legitimately click “SMALL ENTITY” on the patent application forms) abandons one application, they can get another application moved up in the system.

I’m not quite sure how abandoning one invention in favor of another protects an inventor, but it’s certainly an option worth discussing with your patent attorney. It’ll save you the cost of a double patent prosecution, if nothing else, but it doesn’t sound like it will protect the abandoned invention at all, so I intend to advise my clients to consider this very carefully before proceeding.

The USPTO is always trying to come up with ways to diminish their backlog of patent applications that await first office actions. Certainly getting an inventor to abandon an application would do that, but at what cost to the inventor?

Clearly, this option is not for everyone. Maybe for some, yes, but not for everyone.

The other thing they’re doing may work better for the reduction of the backlog in the long run: they’ve got a hiring frenzy going on right now. They’re looking for warm bodies to throw at the backlog (not always a good thing, but not always a bad thing, either). If you have any sort of technical expertise at all, and you like the idea of living in the DC/northern Virginia area, visit their website at www.uspto.gov to apply for the position of Patent Examiner. They have many open slots.

"First-to-file" rule being looked at by Senate – to decrease the patent application backlog??

According to the Wall St. Journal today:

—————–

“Although the office has traditionally operated with a backlog, the pile has increased in recent years. Even though there has been a drop-off in applications during the recession, it hasn’t helped examiners catch up. One reason is that overtime has been cut, so examiners spend fewer hours processing applications. What’s more, because the office is entirely funded by user fees, the dropoff has left it with a budget gap.

“Patent rules haven’t changed significantly in five decades, despite many attempts by Congress.

“This year, a fragile compromise between pharmaceutical and technology companies on a Senate bill could make a difference. The bill would institute a “first-to-file” system that would award patents based on the date an application is filed, rather than on the date of invention was made.”

—————–

A first-to-file patent priority system. Wow.

That would match with much of the rest of the world’s patent practice, so it would go a long way toward harmonization of worldwide patent law. It is, though, a BIG break from the way the US has traditionally handled patent application priority, based on a first-to-invent system. Here’s the difference:

A first-to-file system is a race to the patent office. Whoever files first wins. The actual date of invention is irrelevant.

A first-to-invent system grants patent rights based on proof of the date of invention. The date of filing is the presumptive date of invention, but the inventor, should an application be filed by someone else on the same invention, has the opportunity to prove that she made the invention first and worked diligently on the invention until the date of filing. This is called an “interference.”

I didn’t know that there were so many interferences before the USPTO that instituting a first-to-file system would make a difference in the patent application backlog. While I’m all for a first-to-file system for reasons of international patent law harmonization, I think it’s folly to believe that instituting a “first-to-file” system would make the least dent in the patent application backlog.

So prove me wrong.

2008 National Medal of Technology and Innovation Awardees Announced

Click here for the story …

“The 2008 National Medal of Technology and Innovation winners are:

•Dr. Forrest M. Bird for his pioneering work in the field of respiratory and cardiopulmonary care including the revolutionary BABYBird®. This device dramatically reduced the infant respiratory failure mortality rate from approximately 70 percent to 10 percent. His more recent medical invention of Intrapulmonary Percussive Ventilation (IPV) ® concepts have reduced pulmonary failure in the most critically injured military and civilian burn patients from about 75 percent to 5 percent. Dr. Bird’s innovations have saved millions of lives.

•Dr. Esther S. Takeuchi for the development of the silver vanadium oxide battery technology which powers the majority of today’s implantable cardiac defibrillators and innovations related to other enabling medical battery technologies that power implantable pacemakers, implantable neurostimulators and left ventricular assist devices. Dr. Takeuchi’s innovations have saved and dramatically improved the quality of hundreds of thousands of human lives.

•Dr. John E. Warnock and Dr. Charles M. Geschke for their pioneering contributions that spurred the desktop publishing revolution and for changing the way people create and engage with information and entertainment across multiple mediums including print, Web and video.

•International Business Machines Corporation for the IBM Blue Gene supercomputer, which re-established United States leadership in high performance computing. Blue Gene’s systems architecture, design and software have delivered fundamental new science, unsurpassed speed and unparalleled energy efficiency, which have had a profound impact on the worldwide high-performance computing industry.”

On a personal note, Dr. Bird’s invention, taken to a new level, saved my daughter’s life about five years ago, so I’m delighted he won this prestigious award. Congratulations are due all around, so congratulations to the 2008 National Medal of Technology and Innovation!

UPDATE: Microsoft Appeals Word Patent-Injunction Case – WSJ.com

The link for the video, in case it doesn’t show up, is here.

UPDATE: Microsoft Appeals Word Patent-Injunction Case – WSJ.com.

As well they should.

Watch for the case to get argued before and decided by the US Court of Appeals for the Federal Circuit, which holds exclusive jurisdiction over patent cases.

The district judge’s ruling does seem to me to be a bit overbearing: Microsoft can’t sell Word because a part of it infringes a patent held by a Toronto-based company called i4i. 14i now has a permanent injunction against Microsoft granted earlier this month.

Your Honor, wouldn’t an enforced license and a hefty money judgment have done the job without threatening the software base of thousands if not millions of companies worldwide who rely on Microsoft Office products to get their own work done?

Don’t get me wrong here: I in no way approve of or endorse Microsoft’s aggressive patent infringing policies. However, Microsoft products are heavily used and therefore needed in the business world, and this ruling potentially disturbs many, many other businesses which are already struggling in the current economy. Requiring businesses to switch software midstream could spell collapse for many small and medium-sized businesses that simply cannot budget for the conversion from Microsoft Word to a new word processing system when the time comes to upgrade (for you know that Microsoft will sue in patent anyone who puts any code that in any way resembles its code for reading Word documents into word processing software…).

And the wheels on the bus go round and round…

Microsoft Faces Permanent Injunction against Selling Word | BNET Technology Blog | BNET

Microsoft Faces Permanent Injunction against Selling Word | BNET Technology Blog | BNET.

The universe just heaved.

Any version of Microsoft Word that reads XML files will have to be pulled from the shelves within 60 days, based on a permanent injunction out of the patent litigation “rocket docket” court, the US District Court for the Eastern District of Texas.

Patents give their owners the right to prevent others from making, using, selling, distributing or importing the covered invention in the United States. Here, a patent held by a company called i4i apparently covers the technology that Microsoft uses to even open .xml documents. Microsoft didn’t license the technology; they, according to the E.D. Tex., infringed the patent throughout their Office products.

Oops.

In re Bilski is Good Law Until the US Supreme Court Says Otherwise (Article – WSJ.com)

Article – WSJ.com. Subscription required after WSJ takes this article off the free space on its site.

In re Bilski is being applied as it waits for its hearing before the US Supreme Court in the fall as Bilski v. Doll. A Ninth Circuit district court judge ruled a business method patent invalid based on the Bilski standard of transformative use. The patent holder, DealerTrak Holdings, Inc., intends to appeal the holding.

This is a good chance for me to take a flying leap of logic and talk about how case law and the courts work in the USA.

We have two court systems: the federal system (which holds exclusive jurisdiction over matters involving federal statutes like patent and copyright) and the states’ systems (which holds jurisdiction over state-based matters like contracts and torts). These systems come in hierarchies. I’ll talk about the federal system only (state systems vary from state to state, but they follow this same basic model).

In the federal system, the lowest court is the district court. These are the trial courts; this is the only place where the parties actually have to show up. This is where juries are sworn, testimony is taken, and a record of the litigation is produced (through transcription and discovery). The record is very, very important. There is at least one district court in every state.

The district court judges, who are Article III judges with lifetime appointments just like their appellate brethren, can appoint, under Article I of the Constitution, so-called “magistrate” judges (I was lucky enough to take my law-school Trial Advocacy class with the New Hampshire magistrate, Hon. James Muirhead). Magistrates handle a lot of pre-trial work; they also sometimes handle the trial, if the parties agree. Magistrates report to the district judges. Magistrates’ appointments are for a term of years, not for life.

The district court judges and magistrates must follow the holdings of every appellate court that sits directly above them as they make their decisions. The Court of Appeals for the Federal Circuit (CAFC) sits above each and every district court in matters where the CAFC has exclusive jurisdiction — like patent matters. This means that the district court judges must know and apply CAFC law when deciding matters that fall under the exclusive jurisdiction of the CAFC, no matter which so-called “circuit” the district court sits in. If the matter does not fall within the exclusive jurisdiction of the CAFC, then the district court must apply the case law of its own individual circuit court of appeals, as well as its own case law. It must also, of course, follow US Supreme Court case law. The district court can overturn its own case law, but it must follow the case law from its own circuit court and the CAFC, and from the US Supreme Court.

The US has 13 circuits (numbered 1-12, and the federal circuit). Each circuit has one regional court of appeals; they hear the cases that come out of the district courts with a decision with which one of the parties is unhappy. They rule based solely on the record of the case (which is why the record is very, very important), the attorneys’ briefs, and sometimes oral arguments, and on existing law, including their own and US Supreme Court case law. It is free to overturn its own case law. It can follow the holdings of other circuits or it can branch out on its own and hold something entirely different.

When there is a split in the circuit courts of appeal on a question of law, the field is ripe for the US Supreme Court to step in to settle the matter (another ripening field for the US Supreme Court is when one of the lower courts rules in a way that they think needs to be examined). The US Supreme Court can pick and choose most of the cases it will hear (there are some that it must hear, specifically those with which original — trial — jurisdiction rests with them, such as disputes between the states), and it does not choose to hear most of the petitions for writs of certiorari (“cert”) that come before it. Denying cert says nothing about the case below; it simply says that the US Supreme Court chooses not to hear the matter.

The US Supreme Court sits above all other courts (both state and federal) in the country. The only case law it must apply (and it is free to overturn this) is its own.

Courts do not like to overturn their own case law. It tends to make something of a splash in the legal world when a court does that, and the higher the court is, the bigger the splash an overturned case makes.

Bilski has been decided by the CAFC. The holding — well, the parties disagree with it; hence the petition for cert to the US Supreme Court. The US Supreme Court granted cert on this one; they will hear and finally decide the questions presented by the case. Until the Nine Wise Ones (or at least a majority of them) say otherwise, the CAFC rule of “transformative use” stands, and by the CAFC ruling the district courts are bound.

In re Bilski again

The US Supreme Court has granted cert on In re Bilski (now styled Bilski v. Doll). The case is now pending before the Nine Wise Ones. Here are the court filings (from the point of view of the USPTO).

Bilski, as you recall, requires that business method patents have some sort of “transformative” characteristic — that is, the invention must somehow transform data or information input into something surprisingly different coming out.

The questions presented to the Court are:

1. “Whether the Federal Circuit erred by holding that a “process” must be tied to a particular machine or apparatus, or transform a particular article into a different state or thing (“machine-or-transformation” test), to be eligible for patenting under 35 U.S.C. § 101, despite this Court’s precedent declining to limit the broad statutory grant of patent eligibility for “any” new and useful process beyond excluding patents for “laws of nature, physical phenomena, and abstract ideas.”

2. “Whether the Federal Circuit’s “machine-or-transformation” test for patent eligibility, which effectively forecloses meaningful patent protection to many business methods, contradicts the clear Congressional intent that patents protect “method[s] of doing or conducting business.” 35 U.S.C. § 273.

I hope Bilski gets overturned; I don’t like its holding. I REALLY hope Bilski gets overturned.

U.S. patent office shortfall worsens: official | Politics | Reuters

U.S. patent office shortfall worsens: official | Politics | Reuters .

Awww…poor babies. They’re collecting “just” $5.9 million per day (yep, you read right) in fee-based revenue and they’re not happy.

Damn. Let’s do the math. $5.9 million/day times 365 days/year … that’s $2,153,500,000 per year. Not bad. Of course, they’re down from $6.9 million per day … same equation, substitute that number and you get $2,518,500,000. Well, heck, they’re still above $2 billion dollars in fee-based revenue. Of course, it’s $365,000,000 less now than they were collecting in fee-based revenue before the recession (if that’s what we’re in) hit….

Still, I have no sympathy. This agency has more than $2 billion dollars per year in fee-based revenue; I could balance that budget with little difficulty. So suck it up, USPTO, and live within your means, just like the rest of us have to do.